Previous close | 2.3300 |
Open | 2.3300 |
Bid | 2.3000 x N/A |
Ask | 2.3300 x N/A |
Day's range | 2.2900 - 2.3400 |
52-week range | 2.0300 - 3.9500 |
Volume | |
Avg. volume | 9,131 |
Market cap | 15.561M |
Beta (5Y monthly) | 1.35 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.2000 |
Earnings date | 27 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Press release, Helsinki, 22 April 2024 at 11 AM (EEST) Nexstim Receives NBS 6 System Order from Clinic in Florida, US Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from a new clinic customer located in Florida, Unites States. Launched in 2023 in the United States and Europe, the NBS 6 is a new Nexstim product generation that brings the usability of the Nexstim system to a new level. The NBS 6 is currently FDA-approved for the treatment of major depres
Company Announcement, Helsinki, 12 April 2024 at 9 PM (EEST) Nexstim Plc Resolved on a New Stock Option Plan 2024H Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that the Board of Directors of Nexstim resolved on 12 April, 2024, to launch a new stock option plan 2024H aimed at the Board of Directors of the Company by virtue of an authorization granted by the Annual General Meeting of Shareholders of the company on March 28, 2024, and according to the AGM resolution. The Company has a
Company Announcement, Helsinki, 28 March 2024 at 1 PM (EET) Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”), announces as follows regarding the resolutions that were adopted at its Annual General Meeting of Shareholders held today on 28 March 2024. 1 PRESENTATION OF THE ANNUAL ACCOUNTS AND CONSOLIDATED ACCOUNTS, RESULT OF THE FINANCIAL YEAR AND DISCHARGE FROM LIABILITY. The annual general meeting adopted the company’s financ